Opioid Induced Constipation Market
Report ID: SQMIG35I2904
Report ID: SQMIG35I2904
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2904 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
116
|Figures:
77
Global Opioid Induced Constipation Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.63 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 7.22% during the forecast period (2026-2033).
The opioid‑induced constipation (OIC) market has drugs, devices, and other supportive therapies that treat the bowel dysfunction caused by long‑term opioid use. Its big relevance is basically tied to how much people are depending on opioids for cancer pain, postoperative pain, and also chronic non‑cancer pain, where up to 70 % of patients end up with constipation. That doesn’t just feel uncomfortable; it also messes with quality of life and medication adherence.
One main factor pushing the global opioid induced constipation (OIC) market growth forward is heightened awareness within healthcare systems and payers regarding opioid‑related adverse events. That awareness turns into real demand for evidence‑based approaches. And as insurers start to link reimbursement to quality‑of‑care metrics, clinicians are more likely to pick peripheral μ‑opioid antagonists in order to cut down hospitalization risk from severe constipation. Real‑world evidence from oncology centers has shown something like a 30 % drop in emergency department visits when naloxegol is used alongside chemotherapy‑induced analgesia. That advantage then opens doors for combination therapy bundle strategies, digital adherence platforms, and specialty pharmacies. In a loop, better outcomes make formulary inclusion easier , and that then supports more investment in research.
AI‑driven analytics is changing the opioid‑induced constipation (OIC) market outlook because it turns patient data into more actionable guidance. With real‑time monitoring of bowel patterns, opioid dosing, and lifestyle factors, clinicians can tailor laxative schedules and adjust the opioid plan before constipation turns severe. Predictive models flag higher‑risk patients, which encourages early intervention and reduces the usual trial and error, especially around prescribing. When these tools integrate with electronic health records, communication gets smoother between pain specialists, gastroenterologists, and pharmacists. So care becomes more coordinated rather than fragmented. As awareness keeps rising about opioid side effects, these data‑centric systems tend to strengthen adherence, lift quality of life, and help healthcare resources get used more efficiently.
Market snapshot - (2026-2033)
Global Market Size
USD 1.52 Billion
Largest Segment
Laxatives
Fastest Growth
Chloride Channel Activators
Growth Rate
7.22% CAGR
To get more insights on this market click here to Request a Free Sample Report
The global opioid-induced constipation market is segmented based on drug class, route of administration, distribution channel, end-user, and region. By drug class, the market is categorized into Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs), Laxatives, and Chloride Channel Activators. Based on route of administration, the market is divided into Oral and Subcutaneous therapies. By distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on end-user, the market is classified into Hospitals, Palliative Care Centers, and Pain Clinics. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
As per the opioid‑induced constipation (OIC) market analysis, Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs) segment is dominant because they directly counteract opioid binding in the gut, so motility gets restored without touching analgesia. Their way of working goes right after the core reason behind constipation, which makes them the go to option for clinicians who are handling chronic pain. That real world relevance is what keeps pushing adoption across different care settings, and it ends up reinforcing their central spot in the market. Also , there is strong clinical evidence on efficacy and safety so prescribers feel more confident. On top of that, reimbursement frameworks are increasingly lining up in favor of these agents, which basically cements their leadership.
At the same time, the laxatives segment is seeing the fastest growth momentum, mostly because newer osmotic formulations are being plugged into multimodal constipation protocols, giving rapid relief with minimal systemic interaction. More people are getting aware of early symptom management, and outpatient use keeps expanding, so manufacturers see fresh expansion chances.
According to the opioid‑induced constipation (OIC) market forecast, the oral route segment leads, largely because it matches patient preference for non-invasive administration, which helps adherence during long term therapy. When people can self administer easily, there are fewer healthcare visits. That lowers the overall treatment load and makes clinicians more comfortable prescribing more broadly across varied settings. This everyday convenience strengthens its market footing. Plus , pharmaceutical innovation has improved taste masking and overall drug stability, so the user experience is better. That improvement supports sustained growth too. These advancements also make combination therapies more practical, which keeps oral solutions integrated into standard pain management regimens.
Meanwhile, the subcutaneous route segment is predicted to achieve the largest opioid‑induced constipation (OIC) market share because new biologic carriers allow targeted delivery, so efficacy can improve while systemic exposure gets minimized. Clinician interest in faster onset formulations is growing, and home infusion services are also expanding, which pushes uptake. That makes this route feel like a catalyst for future expansion. The same trend also draws investment into specialized delivery devices, and that further speeds up adoption.
To get detailed segments analysis, Request a Free Sample Report
As per the opioid‑induced constipation (OIC) market regional forecast, North America seems to lead the market because it has a mature healthcare framework, lots of awareness about opioid related adverse effects, and basically widespread use of evidence based management protocols. Clinical guidance keeps pushing proactive bowel management, so specialized therapies get pulled in early, almost as a routine thing. On top of that, solid reimbursement rules and strong payer backing help patients get to newer options faster. Also, there are ongoing research partnerships between academic hubs, pharmaceutical groups and even patient advocacy circles, and they just keep feeding innovation. The regulatory setup in the region walks a line between safety and quicker product launches, which locks in its leadership role in tackling opioid induced constipation.
United States Opioid Induced Constipation Market
The Opioid Induced Constipation market outlook in the United States is shaped by an advanced web of specialty gastroenterology practices plus integrated health systems that push comprehensive pain management. Clinicians often use multimodal approaches, blending pharmacologic tactics with non pharmacologic interventions, which is the common rhythm. Payer rules frequently favor step wise care pathways, so escalation to targeted therapies happens without too much delay. Meanwhile patient education efforts and digital health tools support adherence, and help with symptom tracking, which adds to the market depth and keeps it steady.
Canada Opioid Induced Constipation Market
In Canada, the Opioid Induced Constipation industry is helped by a publicly funded healthcare system that leans into fair access to effective bowel regimens. Provincial formularies tend to revise their coverage expectations in line with clinical evidence, so novel agents can be used more widely. There are also collaborative care models where pharmacists, nurses, and physicians coordinate closely, making early detection of constipation symptoms more likely. At the same time, professional development programs boost clinician attention on this issue, and patient centered resources help individuals feel more involved in their own treatment journeys.
The European opioid‑induced constipation (OIC) market penetration is driven by harmonized regulatory standards and a rising focus on patient reported outcomes across different countries. Health authorities are emphasizing quality of life metrics, so constipation management starts showing up inside chronic pain protocols. Cross border academic collaborations speed up clinical research, and that produces stronger evidence for emerging therapies. Market players also react to the growing demand by tailoring offerings to local preferences, plus adding digital health platforms to track symptoms. Taken together supportive reimbursement policies, higher clinician awareness, and patient advocacy create a fertile base for sustained market growth.
Germany Opioid Induced Constipation Market
The Opioid Induced Constipation sector in Germany is mostly influenced by a strong pharmaceutical manufacturing base, along with clinical networks that are already used to guideline led care. Reimbursement frameworks tend to reward evidence based interventions, and that encourages faster uptake of innovative agents. Multidisciplinary pain clinics commonly evaluate bowel function, so therapeutic intervention starts earlier rather than later. National health insurance provides broad coverage, while professional societies push continuous education, keeping the market position very strong.
United Kingdom Opioid Induced Constipation Market
In the United Kingdom, the Opioid Induced Constipation market is expanding quickly, largely because integrated care pathways embed constipation screening across both primary and secondary care. NHS formularies increasingly back newer treatment options, and digital prescription systems make access feel more streamlined. Patient advocacy groups also promote awareness and this shifts clinical practice toward proactive management. Plus, collaborative research efforts between universities and industry keep product development moving, which makes the United Kingdom a fast moving segment.
France Opioid Induced Constipation Market
The Opioid Induced Constipation market in France is starting to take a more preventive direction as clinicians become more focused on opioid side effects. The national health system encourages multidisciplinary coordination, linking pain specialists with gastroenterology services. Reimbursement policies are adjusting, so a wider set of therapeutic options can be considered, and ongoing medical education programs improve practitioner confidence in constipation management. On top of that, patient empowerment initiatives are growing too, and they help push demand toward effective solutions that feel more patient friendly.
Asia Pacific is moving fast through rapid modernization of healthcare delivery and it looks like there’s more emphasis on chronic disease management. At the same time regulatory agencies are streamlining approval pathways for specialized gastrointestinal agents, which helps companies get to market more quickly. Also, more urbanization and rising awareness about opioid side effects are pushing demand for constipation therapies that feel more dedicated than before. In parallel, regional partnerships between multinational firms and local distributors improve market penetration, while telemedicine platforms support better patient monitoring plus adherence. Put together, these factors place Asia Pacific as an increasingly influential part of the global landscape.
Japan Opioid Induced Constipation Market
The Opioid Induced Constipation Market in Japan benefits from a well-organized healthcare system that blends advanced diagnostics with personalized treatment plans. National guidelines stress early action, so physicians tend to weave targeted therapies alongside conventional laxatives. Reimbursement frameworks are also shifting to fit newer products, and hospital formularies end up being a key driver for adoption. Ongoing investment in clinical research keeps strengthening the evidence base, which supports continued market momentum.
South Korea Opioid Induced Constipation Market
The Opioid Induced Constipation Market in South Korea is supported by strong health insurance coverage and an extensive network of specialty clinics, especially those centered on pain management. Providers are increasingly viewing bowel health as essential within opioid therapy, so they perform routine checks and escalate treatment earlier when needed. Government initiatives that promote digital health tools help patients engage more actively, and this tends to improve compliance. Meanwhile collaborative work between local manufacturers and international partners widens product availability, helping market development move forward.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Use Of Opioids For Pain
Growing Awareness Of Constipation Management
Stringent Regulatory Requirements
Limited Patient Adherence To Therapies
Request Free Customization of this report to help us to meet your business objectives.
Key players moving around in the market , look like Takeda Pharmaceutical , AstraZeneca plc , Bausch Health (Salix Pharmaceuticals) , Mallinckrodt Pharmaceuticals , Merck & Co Inc , RedHill Biopharma , GlaxoSmithKline (Theravance Biopharma Inc) , Shionogi & Co Ltd , and Novartis AG (Sandoz). These market participants are basically always trying to push new product development along , they’re also hopping into M&A deals and setting up other strategic collaborations, to open fresh routes in the market. Some of the most noticeable recent pushes include AstraZeneca’s arrangement with Forest Laboratories to co‑develop new OIC therapies and HealthCore’s purchase of a smaller biotech niche, so its pipeline can grow faster, which in turn makes competition feel more intense and innovation keeps speeding up.
Top Player’s Company Profile
Recent Developments in the Opioid Induced Constipation Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global opioid‑induced constipation market is propelled mainly by the growing use of opioid analgesics for chronic, postoperative, and palliative pain, which steadily enlarges the group of patients that require targeted bowel therapeutics. A second major driver is the rising awareness—among clinicians as well as patients—about how constipation can harm quality of life, and that is pushing earlier intervention. At the same time, the market faces constraints from strict regulatory obligations that extend development schedules and raise overall expenses, which makes it tougher for new players to enter. North America is still the leading region, largely due to its established healthcare infrastructure and strong payer support, and the PAMORAs drug class continues to lead the segment landscape, reflecting its demonstrated efficacy and favorable reimbursement conditions.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.52 Billion |
| Market size value in 2033 | USD 2.85 Billion |
| Growth Rate | 7.22% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Opioid Induced Constipation Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Opioid Induced Constipation Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Opioid Induced Constipation Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Opioid Induced Constipation Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Opioid Induced Constipation Market size was valued at USD 1.52 Billion in 2024 and is poised to grow from USD 1.63 Billion in 2025 to USD 2.85 Billion by 2033, growing at a CAGR of 7.22% during the forecast period (2026-2033).
HealthCore, Forest Laboratories, Progenics Pharmaceuticals and AstraZeneca dominate the opioid‑induced constipation market, each expanding their product portfolios through targeted collaborations, selective acquisitions and technology‑driven development. Recent strategic moves include AstraZeneca’s partnership with Forest Laboratories to co‑develop novel OIC therapies and HealthCore’s acquisition of a niche biotech to broaden its pipeline, intensifying competition and accelerating innovation. 'AstraZeneca (Movantik)', 'Salix Pharmaceuticals (Relistor)', 'Bausch Health (Relistor)', 'Shionogi USA (Symproic)', 'Daiichi Sankyo', 'Purdue Pharma', 'Nektar Therapeutics', 'Progenics Pharmaceuticals', 'Mallinckrodt Pharmaceuticals', 'Pfizer Inc.', 'Actavis (Allergan/AbbVie)', 'Norgine BV', 'Almirall SA', 'Sucampo Pharmaceuticals', 'Takeda Pharmaceutical', 'Synergy Pharmaceuticals (Bausch)', 'Ironwood Pharmaceuticals', 'Ardelyx Inc.', 'Theravance Biopharma', 'RedHill Biopharma'
Increasing prescriptions of opioid analgesics across chronic pain, postoperative care, and palliative settings expands the patient pool at risk of opioid induced constipation. Clinicians increasingly recognize constipation as a quality‑of‑life issue, prompting referrals for targeted therapies. This heightened clinical focus amplifies demand for pharmaceutical agents and supportive care products designed to mitigate bowel dysfunction, thereby propelling market expansion through broader adoption and integration into standard pain management protocols. Pharmaceutical firms respond by expanding pipelines, investing in education, and collaborating with healthcare providers to ensure seamless therapy adoption.
Integrated Digital Therapeutics: The market is witnessing rapid incorporation of digital health platforms that enable remote monitoring of bowel function, adherence tracking, and personalized titration of opioid‑induced constipation therapies. Clinicians leverage AI‑driven analytics to predict symptom trajectories, while patients benefit from mobile applications that provide real‑time guidance and education. This convergence of pharmacology and technology fosters a more proactive care model, accelerates therapy adjustments, and expands market reach through telehealth integration, positioning digital therapeutics as a core growth driver.
Why does North America Dominate the Global Opioid Induced Constipation Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
